AstraZeneca Results Presentation Deck

Late-stage pipeline events in the 2021-2022 timeframe Busy news flow continues; Phase III readouts increase into 2021 Regulatory decision Regulatory submission acceptance and/or submission Key Phase III data readout H1 2021 Tagrisso-adjuvant NSCLC (EGFRM) (EU) Koselugo - NF1 (EU) Farxiga - CKD (US) Symbicort - mild asthma (EU) Calquence - CLL (R/R) (ELEVATE R/R) Fasenra - nasal polyps tezepelumab - severe asthma COVID-19 vaccine - COVID-19 (US, JP) AZD7442 - SARS-CoV-2 Imfinzi +/-treme - NSCLC (1L) (POSEIDON) (OS) AZD7442 - SARS-CoV-2 Status as of 30 April 2021. 1. Based on a planned interim analysis as communicated by Daiichi Sankyo in Q2 of their fiscal year 2021. 35 H2 2021 Lynparza - prostate cancer (2L) (CN) Forxiga - CKD (EU, JP, CN) Brilique - stroke (THALES) (EU, CN) roxadustat - anaemia in CKD (US) anifrolumab - lupus (SLE) (US, EU, JP) Imfinzi - unresectable, Stage III NSCLC (PACIFIC-2) Imfinzi +/-treme - NSCLC (1L) (POSEIDON) Imfinzi +/-treme - liver cancer (1L) Lynparza - adjuvant breast cancer Lynparza - prostate cancer (1L, castration-resistant) Enhertu - breast cancer (2L, HER2+) Imfinzi - unresectable, Stage III NSCLC (PACIFIC-2) Imfinzi - NSCLC (1L) (PEARL) Imfinzi +/- treme - liver cancer (1L) Lynparza - prostate cancer (1L, castration-resistant) Enhertu - breast cancer (2L, HER2+)¹ Farxiga - HF (HFpEF) PT027- asthma nirsevimab - RSV (MEDLEY) 2022 Imfinzi - ES-SCLC (CN) Imfinzi - NSCLC (1L) (PEARL) Imfinzi - limited-stage SCLC Imfinzi - liver cancer (locoregional) Imfinzi - biliary tract cancer Lynparza - ovarian cancer (3L, BRCAM) Enhertu - breast cancer (3L, HER2+) (Phase III) Enhertu - breast cancer (HER2 low) Calquence - CLL (CN) Koselugo - NF1 (JP, CN) Farxiga - HF (HFpEF) roxadustat - anaemia in myelodysplastic syndrome PT027 - asthma nirsevimab - RSV Imfinzi - limited-stage SCLC Imfinzi - liver cancer (locoregional) Imfinzi - biliary tract cancer Enhertu - breast cancer (3L, HER2+) (Phase III) Enhertu - breast cancer (HER2 low) roxadustat - anaemia in myelodysplastic syndrome 3

View entire presentation